Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 24

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Aravis Venture I LP40.1%
• Astellas Venture Capital, LLC40.1%
• Auriga Ventures III40.1%
• Baltisches Haus Limited40.1%
• BioMedInvest II LP40.1%
• A/S Dansk Erhvervsinvestering40.1%
• Entrepreneurs Fund General Partners Limited40.1%
• Evolva Holding SA40.1%
• Mona Lisa Capital SA40.1%
• Novartis Bioventures Ltd40.1%
• Renaisance PME fondation suisse d investissement / Mona Lisa40.1%
• Sunstone Life Science Ventures Fund I K/S40.1%
• Symbion Capital I A/S40.1%
• Wellington Partners Ventures III Life Science Fund L.P40.1%
• Wellington Partners Ventures III Life Science Network Fund L40.1%
• Neil Goldsmith40.1%
• Alexandra SantAna Sørensen40.1%
• Pascal Longchamp40.1%
• Jakob Dynnes Hansen40.1%
• Jutta Heim40.1%
• PM Murali40.1%
• Ventureast Trustee Company P Limited40.1%
• APIDC Venture Capital P Limited40.1%
• Vaekstfonden40.1%

Notice details

Beneficial owner

Aravis Venture I LP

On December 13, 2010 the members of the group (the Lock-up Group) have agreed to partially extend the lock-up undertaking entered into prior to the merger between Arpida Ltd. (now Evolva Holding SA) with Evolva SA with regard to a part of their shares in Evolva Holding SA (the Shares) and conversion rights (as previously disclosed). On 30 May 2011, the participants in Danske Innovationsinvestering (DI), one of the members of the Lock-up Group, decided to liquidate the DI fund and distribute the Evolva shares to its shareholders: Vaekstfonden and A/S A/S Dansk Erhvervsinvestering. The purpose of the present disclosure is to show the changed composition of the Lock-up Group. Additional information can be downloaded from the Evolva website www.evolva.com/press-investors/investors/disclosure-shareholdings